Biotech Values

[jq1234]

Did NVO discuss the ultra-fast acting insulins, either their own candidates or buzz about any desire to in-license such a candidate?

Yes, NVO talked about next generation of insulin in great detail. Basically the focus are three directions: ultra long acting (ULA), ultra fast acting (UFA), oral. The most advanced in NVO pipeline is ULA degludec which is in phase III currently. Oral and UFA are in phase I.

It was a great presentation, a must for anyone interested in diabetes/insulin market. I believed and continue to believe anyone investing in pharma/biotech must have large exposure to diabetes market, which is growing, and will continue to grow really fast worldwide.